Lonza to start manufacturing Moderna’s Covid-19 vaccine this December

Lonza’s new building dedicated to the manufacturing of Moderna’s Covid-19 vaccine will be operational starting December 2020. 300 million doses will be produced annually at the Visp site.

In May 2020, Lonza signed a major agreement with the American biotechnology company Moderna Therapeutics to help manufacture a promising vaccine against Covid-19 utilizing the new mRNA technology.

At an estimated cost of CHF 210 million, the construction of the production infrastructure at Lonza’s Visp site in the canton of Valais was carried out over a period of eight months instead of the more than two years generally required for a project of this magnitude. “Everything will be ready for the production of the first doses in December,” assured site manager Torsten Schmidt.

In time, “three production lines will be installed, each with a production capacity of approximately 100 million doses per year,” explains Renzo Cicillini, director of Lonza Visp. The company plans to hire 200 people to produce the new vaccine.

A vaccine using innovative technology

Moderna’s vaccine uses innovative technology, which consists in making the body’s cells produce the main antigen of the virus using an intermediate protein to stimulate an immune response.

The advantage of this so-called “messenger RNA (mRNA)” vaccine is that it takes less time to develop. Of the more than 200 vaccine candidates worldwide, eight have reached Phase 3, including two using mRNA technology. Moderna’s vaccine is one of the three most advanced Western projects. For instance, the Swiss Confederation has an agreement with the US company for the delivery of 4.5 million doses of the vaccine.

HubsGoGlobal is a platform under the PharmaBoardroom brand that focuses on the competitive advantages of the Hub and its value proposition in terms of strategic, operational, financial, talent and lifestyle aspects.

PharmaBoardroom provides industry trends, news and reports from all over the world. This site is for senior professionals who want to understand local and global markets.

CONTACT

Greater Geneva Bern area is an initiative of the cantons of
Bern, Fribourg, Vaud, Neuchâtel, Geneva and Valais.

World Trade Center – Av. de Gratta-Paille 2
PO Box 252
1000 Lausanne 22 – Switzerland

CONTACT

Copyright: All rights reserved. No part of this site maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this website, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

2021 © PharmaBoardroom